Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lipocine (LPCN) EBIT (2016 - 2025)

Lipocine's EBIT history spans 13 years, with the latest figure at -$3.4 million for Q3 2025.

  • For Q3 2025, EBIT fell 27.77% year-over-year to -$3.4 million; the TTM value through Sep 2025 reached -$5.2 million, down 155.99%, while the annual FY2024 figure was $1897.0, 100.06% up from the prior year.
  • EBIT reached -$3.4 million in Q3 2025 per LPCN's latest filing, down from -$2.4 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of $11.9 million in Q4 2023 to a low of -$7.0 million in Q3 2023.
  • Average EBIT over 5 years is -$1.2 million, with a median of -$3.0 million recorded in 2021.
  • Peak YoY movement for EBIT: skyrocketed 564.84% in 2023, then tumbled 164.86% in 2025.
  • A 5-year view of EBIT shows it stood at $9.5 million in 2021, then plummeted by 126.94% to -$2.6 million in 2022, then surged by 564.84% to $11.9 million in 2023, then crashed by 77.3% to $2.7 million in 2024, then crashed by 224.37% to -$3.4 million in 2025.
  • Per Business Quant, the three most recent readings for LPCN's EBIT are -$3.4 million (Q3 2025), -$2.4 million (Q2 2025), and -$2.1 million (Q1 2025).